Actively Recruiting
Blood-Based Molecular Biomarkers and Response to Transcranial Magnetic Stimulation in Treatment-Resistant Depression
Led by Gulhane Training and Research Hospital · Updated on 2026-09-11
55
Participants Needed
2
Research Sites
24 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating how blood-based biomarkers relate to treatment response in patients with treatment-resistant depression TRD. The study aims to identify molecular signatures in plasma proteomic and metabolomic profiles that can predict how patients respond to transcranial magnetic stimulation TMS therapy, helping to personalize treatment and improve outcomes. This research aligns with the move toward precision medicine in psychiatry and seeks to reduce healthcare costs by enhancing clinical decision-making. Participants diagnosed with TRD will receive 20 sessions of TMS over four weeks using the MagVenture X100 device. Each session delivers 1,800 pulses of intermittent theta burst stimulation targeting the left dorsolateral prefrontal cortex. Motor thresholds will be assessed weekly to adjust treatment intensity to 90% of the resting motor threshold. Blood samples will be collected before the first session and after the final session for proteomic and metabolomic analysis. A control group of healthy individuals will provide blood samples at one time point for baseline comparison. During the study, participants will undergo psychiatric assessments including depression severity scales and sleep quality questionnaires at baseline and after treatment. Researchers will analyze molecular changes related to TMS response using advanced bioinformatics tools. Outcomes include identifying protein and metabolite changes linked to treatment response, monitoring depression severity changes, documenting any side effects such as headaches or seizures, and exploring correlations with medication history. The total study duration for participants is four weeks of treatment with assessments before and after therapy.
CONDITIONS
Brief Title
Molecular Signatures of TMS Response in Treatment-Resistant Depression
Research Team
B
BEYAZIT GARİP, Medical Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here